Medtech innovator Xyall closes € 7.6 million financing round to globally roll out its unique high-tech molecular pathology laboratory solutions

Delivers faster, more accurate and efficient automated tissue dissection

The Xyall BV, a next-generation innovator in molecular pathology, has secured an investment of € 7.6 million from a consortium led by Capricorn Partners via their Capricorn Healthtech Fund II, alongside existing investors Sioux Technologies, BOM Brabant Ventures, Health Investment Partners, and several private investors.

The funding will support the global roll out of Xyall’s Tissector TableTop, an automated tissue dissection system that is already in use at more than 15 molecular pathology laboratories. This installed base spans laboratories in tier 1 commercial, academic, pharma and research institutes in the United States, demonstrating strong and growing demand for scalable, reliable automation in molecular diagnostics.

Tissue dissection remains a largely manual and labor-intensive process, relying on subjective assessment and carrying a significant risk of error and cross-contamination. Xyall is transforming this critical workflow step by combining high-resolution slide imaging, precise image registration, workflow optimization, and high-precision robotics into a fully automated solution.

Introduced in 2023, the Tissector Table Top was developed to address practical, day-to-day challenges faced by molecular pathology laboratories. Its adoption by leading hospital laboratories highlights both the clinical relevance and operational value of the system.

Guido du Pree, CEO of Xyall, commented:

• Molecular diagnostics play a key role in determining the most appropriate treatment, particularly in oncology. Laboratories are under increasing pressure to deliver results faster and more accurately, while facing a global shortage of specialized staff. The fact that the Tissector Table Top is already deployed in more than fifteen high standing laboratories confirms that we are addressing a real and urgent need.”

In current practice, pathologists manually mark Regions of Interest (ROIs) on hematoxylin and eosin (H&E) stained slides. Laboratory technicians then visually translate these markings to dissection slides, manually scraping the tissue and collecting it for downstream analysis. This workflow is time-consuming, difficult to scale, and increasingly strained by the global shortage of laboratory technicians.

Du Pree added:

• Over the past decade, PCR and next-generation sequencing technologies have advanced rapidly. However, the critical step of selecting tumor tissue for molecular analysis has remained largely manual, subjective, and imprecise. With our fully automated tissue dissection solutions, Xyall provides the missing link between morphological and molecular diagnostics.”

Dick Sietses, Investment Partner at Capricorn Partners, said:

• Xyall enables pathology labs to operate more efficiently, and the evidence shows that it also supports more accurate diagnoses — particularly in fields like oncology where personalized treatment plans are essential. Xyall is at the beginning of a period of rapid growth across both research and clinical laboratories. This investment will help the company accelerate its development and establish itself as a global leader in this domain.”

Monique Dullens, Investment Manager at BOM added:

• At BOM, we invest in companies that help address pressing societal challenges and strengthen the quality and accessibility of healthcare. Xyall’s technology has the potential to significantly improve the accuracy and efficiency of molecular pathology, supporting better diagnostics for patients worldwide. The company is showing impressive progress in commercial traction and technological capability, and we see significant global potential. With the addition of an experienced new investor, the consortium is even better positioned to support Xyall as they scale their impact in molecular pathology."